Clinical trials: Drug Drug Interaction (DDI)
Healthy
Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI
Evaluation and validation of metabolic markers for the assessment of CYP3A activity and prediction of drug-drug interaction in Korean healthy subjects.
- Trial name
- CYP3A_weak (NCT02328443)
- Testing
- Midazolam, itraconazole, rifampicin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Prostate Cancer Patients
The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
- Trial name
- NCT04676035
- Testing
- Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Male Volunteers
A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol
The purpose of this study is to assess the potential drug-drug interaction of CHF10196 (a dipeptidyl peptidase 1 inhibitor) and its metabolite on the pharmacokinetics of dabigatran (a P-glycoprotein substrate) and Rosuvastatin (a…
- Trial name
- NCT07744386
- Testing
- Dabigatran Etexilate, Rosuvastatin, CHF10196
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy Volunteer
Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor
An open label, multicentre, randomised, 2-cohort, sequential and crossover study to assess the relative oral bioavailability of MT-7117 higher content tablets versus MT-7117 lower content tablets and the pharmacokinetics of…
- Trial name
- MT-7117 BA DDI (NCT03688022)
- Testing
- MT-7117, PPI, Acidic beverage
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Malaria
Tafenoquine/Chloroquine DDI Study
DDI study of Tafenoquine and Chloroquine
- Trial name
- NCT00871156
- Testing
- Chloroquine, Tafenoquine
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of Morphothiadine Mesilate/Ritonavir combined with Entecavir or Tenofovir Disoproxil Fumarate in healthy subjects
- Trial name
- NCT03662568
- Testing
- GLS4, RTV, ETV
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Healthy Volunteers
A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
The purpose of this study is to determine the effect of baricitinib on the levels of digoxin in the blood stream and how long it takes the body to remove digoxin.
- Trial name
- NCT01859078
- Testing
- Baricitinib, Digoxin
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Adult Subjects
A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.
- Trial name
- NCT04008186
- Testing
- Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy
Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors
Evaluation and validation of metabolic markers for the prediction of drug-drug interaction of various CYP3A4 substrates (sildenafil) and inhibitors (erythromycin/itraconazole) in healthy male subjects
- Trial name
- NCT02975037
- Testing
- Sildenafil, Clarithromycin, Itraconazole
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Infection, Human Immunodeficiency Virus
A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)
This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested.
- Trial name
- NCT02480881
- Testing
- BMS-663068, Oral Contraceptive, Loestrin 1.5/30
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Male, Healthy Normal Subjects
Rifampin Drug-Drug Interaction Study With Lurasidone HCl
The effect of rifampin on the pharmacokinetics of lurasidone
- Trial name
- NCT01082276
- Testing
- Lurasidone HCl
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Nocturia
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon
The purpose of this study is to investigate the potential for co-administration of strong inhibitors or inducers of CYP3A4 to alter the pharmacokinetics of fedovapagon.
- Trial name
- NCT02440841
- Testing
- fedovapagon, Itraconazole, rifampicin
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
HCV Infection
Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
Background: Currently used direct-acting antivirals (DAA) share pharmacokinetic pathways with many comedications commonly used in patients with chronic hepatitis C virus (HCV) infection, therefore drug-drug interactions (DDI)…
- Trial name
- NCT06928259
- Where
- 4 sites in Spain
- Volunteers
- 728 people
- Sponsor
- University of Seville
Healthy
Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers
Study to characterise the effects of concurrent tipranavir (TPV) and ritonavir (RTV) administration on the single dose pharmacokinetics of didanosine (ddI), to characterise the effects of single-dose ddI on the pharmacokinetics…
- Trial name
- NCT02251873
- Testing
- TPV + RTV (low dose), TPV + RTV (high dose), ddl
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Erectile Dysfunction
Drug-Drug Interaction (DDI) Study for TPN171H
The primary objective of this study was to assess the effect of rifampicin,a cytochrome P450 3A4 enzyme (CYP3A4) induction, on the pharmacokinetics (PK) of TPN171H in chinese healthy male subjects ,and assess the effect of…
- Trial name
- NCT06090123
- Testing
- TPN171H, Itraconazole, Rifampicin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Healthy Subjects
A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects
This is a four-part, single-center, open-label, single-sequence crossover phase I clinical study to characterize the Drug-Drug Interaction (DDI) potential of DBPR108 at steady-state with Metformin hydrochloride, Glibenclamide…
- Trial name
- NCT04859452
- Testing
- DBPR108 tablets, Metformin hydrochloride tablets, Glibenclamide tablets
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Drug Drug Interaction
Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers
A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone when Administered Concurrently in Healthy Volunteers
- Trial name
- NCT04939467
- Testing
- Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral Tablet
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Blade Therapeutics
Osteoarthritis
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions(DDI) Among Osteoarthritis Patients
Using a retrospective database analysis, OA patients taking at least one CYP450-metabolized opioid (codeine, fentanyl, hydrocodone, methadone, oxycodone, or tramadol) and at least one other prescription drug metabolized via the…
- Trial name
- NCT01177267
- Volunteers
- 10,000 people
- Sponsor
- NEMA Research, Inc.
Healthy Volunteer, Pharmacokinetics
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
This is a Phase 1, open-label, three-part, study in approximately 96 healthy adult participants between 18 and 55 years of age (both inclusive) (16 participants in Part 1, 20 participants in Part 2 and , and approximately 60…
- Conditions
- Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI)
- Trial name
- NCT06733675
- Testing
- Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
RSV Infection, Drug Drug Interaction (DDI)
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants.
- Trial name
- NCT06847464
- Testing
- EDP-323, Itraconazole, carbamazepine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc